Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.06.2012 | original report | Ausgabe 2/2012

memo - Magazine of European Medical Oncology 2/2012

Treatment outcome in AML: a single-centre experience in an unselected patient cohort

memo - Magazine of European Medical Oncology > Ausgabe 2/2012
MD Kathrin Strasser-Weippl, MD Martin Schreder, MD, PhD Niklas Zojer, MD, PhD Heinz Ludwig



Data on prognostic factors and treatment outcomes in patients with acute myeloid leukemia (AML) are usually based on highly selected patient groups. We analysed a cohort of unselected consecutive patients with AML diagnosed more than 10 years at a single institution.

Patients and methods

Treatment outcome and prognostic factors were retrospectively analysed in 147 AML patients. Treatment was selected according to study protocols of the OSHO (East German Study Group for Hematology and Oncology) if patients were eligible.


Median age at diagnosis was 68 years. Eighty-eight (59.9 %) patients were treated with curative intent, palliative treatment was given to 27.2 %, and supportive therapy only to 12.9 % of patients. Of patients aged £ 60 years, 97.7 % were treated with curative intent, versus only 43.7 % of those aged > 60 years. Curative treatment resulted in complete remission in 70 %, a median survival of 15.3 months, a significantly decreased early death rate (35 versus 68.4 %,P < 1 ´ 10 8), and significantly prolonged survival compared to all other patients. This was also true for the sub-group of patients aged > 60 years. In multivariate analysis, age > 60 years, high cytogenetic risk, thrombocytopenia, leukocytosis and non-curative treatment intent emerged as risk factors for poor survival.


Outcome and prognostic parameters in unselected consecutive patients with AML treated in a single institution were found to be similar to those obtained in larger more selected patient cohorts. Our results confirmed that elderly patients should be treated with intensive treatment whenever possible to improve early death rate and overall survival.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 2/2012

memo - Magazine of European Medical Oncology 2/2012 Zur Ausgabe